Search the Newsreel

Revvity outlines 2026 organic growth of 4% to 5% and adjusted EPS of $5.30 to $5.40, driven by diagnostics momentum and AI-linked demand

Earnings Call Insights: Revvity (RVTY) Q2 2026 MANAGEMENT VIEW * "I'm pleased to report that Revvity delivered strong results in the second quarter with pro forma organic growth of 3%, resulting in total revenue being above the high end of our expectations," said (CEO, …

Earnings call transcript: Revvity beats Q2 2026 estimates, but shares fall premarket

Revvity (RVTY) announced strong Q2 2026 results, exceeding adjusted EPS and revenue estimates, driven by organic growth, wider margins, and increased demand linked to AI. Despite the beat and raised full-year guidance for organic growth, operating margin, and EPS, the company's shares fell in …

Revvity Inc. stock underperforms Tuesday when compared to competitors

Revvity Inc. (RVTY) stock fell 3.32% on Tuesday, closing at $111.39, even as the broader market, including the S&P 500 Index and Dow Jones Industrial Average, saw significant gains. The company's stock was also 5.84% below its 52-week high reached on January 22nd.

Revvity, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 05, 2026

Revvity, Inc. announced its financial results for the second quarter and six months ended July 05, 2026. For the second quarter, sales increased to $729.69 million from $720.28 million year-over-year, while net income slightly decreased to $51.82 million. Diluted EPS for the quarter was …

Revvity Tops Second-Quarter Estimates and Lifts Full-Year Outlook

Revvity, Inc. (NYSE:RVTY) reported strong second-quarter 2026 results, surpassing analyst expectations for both earnings and revenue. This performance led the health sciences company to raise its full-year guidance, with increased investments planned due to tariff refunds. The Diagnostics division was a key growth driver, …

Revvity Releases Q2 2026 Financial Results

Revvity, Inc. reported strong Q2 2026 financial results, exceeding Wall Street's EPS estimates by 12.8% with adjusted EPS of $1.41 and revenue of $729.7M. The Diagnostics segment led growth, and the company raised its full-year 2026 guidance for adjusted EPS and revenue, reflecting confidence …

Revvity (RVTY) Q2 Earnings and Revenues Surpass Estimates

Revvity (RVTY) reported strong Q2 results, with earnings of $1.41 per share and revenues of $729.69 million, both exceeding Zacks Consensus Estimates. The company has consistently surpassed EPS estimates over the last four quarters, and its stock has gained 19.1% year-to-date. Revvity currently holds …

Revvity deal to divest China immunodiagnostics; close expected 2027

Revvity (NYSE: RVTY) announced strong financial results for the second quarter of 2026, with adjusted EPS from continuing operations of $1.41, surpassing expectations. The company also entered a definitive agreement to divest its China Immunodiagnostics business, which represented approximately 6% of its fiscal year …

Revvity (NYSE:RVTY) Reports Upbeat Q2 CY2026

Revvity (NYSE:RVTY) reported strong Q2 CY2026 results, exceeding market expectations with a 7.2% year-on-year revenue increase to $729.7 million and non-GAAP EPS of $1.41, a 15.9% beat. The company also raised its full-year revenue and adjusted EPS guidance, indicating an encouraging outlook. Despite past …

Revvity beats estimates, raises guidance as stock jumps By Investing.com

Revvity, Inc. (NYSE:RVTY) reported strong second-quarter results, surpassing analyst expectations with adjusted EPS of $1.41 and revenue of $730 million. The health science solutions provider also raised its full-year 2026 guidance, projecting revenue of $2.83-$2.86 billion and pro forma adjusted EPS of $5.30-$5.40, driven …

Revvity (RVTY) Q2 2026 Earnings

Revvity (RVTY) reported strong Q2 2026 earnings, with EPS of $1.41 surpassing estimates by 15.9% and revenue of $730 million exceeding expectations by 3.8%. The Diagnostics segment was a key driver with 11% organic growth, offsetting a decline in Life Sciences. Management raised full-year …

Earnings Flash (RVTY) Revvity, Inc. Reports Q2 Revenue $729.7M, vs. FactSet Est of $703.0M

Revvity, Inc. (RVTY) announced its Q2 revenue of $729.7 million, surpassing FactSet's estimate of $703.0 million. The company also reported Q2 adjusted EPS of $1.41 per share, exceeding the FactSet estimate of $1.21. Furthermore, Revvity expects its full-year 2026 revenue to be in the …

Revvity, Inc. Bottom Line Drops In Q2

(RTTNews) - Revvity, Inc. (RVTY) revealed a profit for second quarter that Drops, from the same period last year The company's bottom line totaled $51.820 million, or $0.47 per share. This compares with $53.948 million, or $0.51 per share, last year. Excluding items, Revvity, …

California State Teachers Retirement System Buys 22,075 Shares of Revvity Inc. $RVTY

Revvity (NYSE:RVTY) Issues Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Revvity, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:RVTY) 2026-08-04

Revvity (RVTY) reported strong Q2 2026 earnings, with EPS of $1.41 surpassing estimates by 15.9% and revenue of $730 million exceeding expectations by 3.8%. The Diagnostics segment was a key driver with 11% organic growth, offsetting a decline in Life Sciences. Management raised full-year …

Revvity Earnings: Strong but Dressed-Up Quarter Boosts 2026 Outlook

Revvity earnings in focus: AI fears test life sciences tools maker By Investing.com

Revvity is facing scrutiny ahead of its Q2 earnings report due to investor concerns that AI adoption could reduce demand for its preclinical research tools. Analysts expect modest earnings growth but a revenue decline, with the earnings call likely to address the "AI loser" …

Multiple Insiders Sold Revvity Shares Presenting Weak Signs For Investors

This article analyzes recent insider selling at Revvity, highlighting transactions by multiple executives and directors. It discusses the volume and value of shares sold, comparing it to the company's market capitalization and past insider activity. The analysis suggests that while not always a definitive …

Revvity (RVTY) To Report Earnings Tomorrow: Here Is What To Expect

Revvity (NYSE:RVTY) is set to report earnings tomorrow, with analysts expecting a 3.9% year-on-year revenue growth after the company missed expectations last quarter. The market anticipates the business will stay on course, as peer companies like Avantor and Thermo Fisher have already reported positive …

ETFs Investing in Revvity, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Revvity, Inc., a company in the medical specialties sector. The ETFs are sorted by their market value and include details such as weight, issuer, management style, focus, expense ratio, AUM, price, change …

The Technical Signals Behind (RVTY) That Institutions Follow

Revvity Inc. (NASDAQ: RVTY) is showing a neutral sentiment across all time horizons, indicating a wait-and-see approach for institutional investors. The article highlights a high-risk reward short setup with a 10.5% downside target versus 0.3% risk. AI-generated trading strategies are provided, including position trading, …

Revvity declares $0.07 quarterly dividend per share

Revvity, Inc. (NYSE:RVTY) has announced a quarterly dividend of $0.07 per share of common stock. This dividend will be paid on November 13, 2026, to shareholders on record by October 23, 2026. Revvity is a health science solutions company with 2025 revenue of $2.9 …

Revvity Keeps Quarterly Dividend at $0.07 a Share, Payable Nov. 13 to Holders of Record Oct. 23

Revvity, Inc. has announced that it will maintain its quarterly dividend at $0.07 per share. The dividend is scheduled to be paid on November 13 to shareholders who are on record as of October 23.

Revvity (NYSE:RVTY) Flaunts Strong Technical Breakout Setup Near 52-Week High

Revvity (NYSE:RVTY) shows a strong technical breakout setup, marked by a high ChartMill Technical Rating of 9/10 and a perfect Setup Quality Rating of 10/10. The stock is consolidating near its 52-week high, with clear support and minimal overhead resistance, presenting an attractive entry …

Revvity Inc (RVTY) Financial Health: Profitability & Balance Sheet Analysis

Revvity Inc (RVTY) has a stable financial status with a current financial score of 7.36, ranking 83rd in the Healthcare Equipment & Supplies industry. The company reported a 6.97% year-over-year increase in its latest quarterly revenue to $711.12 million, and a 3.60% year-over-year increase …

Revvity, Inc. (0KHE) Q3 2024 Earnings Report - Results, Call & Slides

Revvity, Inc. (0KHE) has released its Q3 2024 earnings report, showing an actual EPS of $1.28, beating the consensus of $1.13 by $0.15. The company also reported actual revenue of $684.05M, surpassing the expected $679.66M, with a YoY revenue growth of 1.98%. Revvity's next …

Revvity (RVTY) Stock Could Be 22% Undervalued As Cash Flow Supports A Bargain

Revvity's stock valuation shows a mixed picture: a Discounted Cash Flow (DCF) analysis suggests it could be 22% undervalued, implying an intrinsic value of $145 per share, while its P/E ratio of 52.9x indicates overvaluation compared to the industry average. The company's share price …

Revvity Inc (RVTY) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Revvity Inc (RVTY), noting its current risk score of 7.44 and its ranking within the Healthcare Equipment & Supplies industry. It details the company's beta value of 1.12, indicating higher volatility compared to the S&P 500. The …

Earnings Preview: Revvity to Report Financial Results Pre-market on August 04

This article announces that Revvity (NYSE: RVTY) is scheduled to release its financial results before the market opens on August 04. Analysts predict the company will report earnings of $1.16 per share, with revenue expectations around $677.67 million for the current fiscal quarter. These …

Revvity Inc (RVTY) Stock Up 3.2% and Still Undervalued -- GF Sco

Revvity Inc (RVTY) shares rose 3.2% to $111.51, reflecting a 15.5% year-to-date gain, yet the stock is considered 7.5% undervalued with a GF Value of $120.57. Despite an attractive valuation rank of 10/10, its growth rank is low at 3/10, and the P/E ratio …

Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Wall Street expects a year-over-year increase in earnings on lower revenues when Revvity (RVTY) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock …

Revvity Inc. $RVTY Stock Holdings Increased by Public Employees Retirement System of Ohio

RVTY|Revvity Inc|Price:111.500|Chg%:+1.030

This article provides a detailed company profile for Revvity Inc (RVTY), a provider of health science solutions. It outlines the company's business scope, including its Life Sciences and Diagnostics segments, and lists key financial data, executive team members, and major shareholders. The company's headquarters, …

Revvity Inc (RVTY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Revvity Inc (RVTY), focusing on its regional revenue contributions. As of the latest update, relevant data for business segments and profit contribution by business have not been disclosed by the company. However, the report highlights that the …

Revvity Inc (RVTY) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Revvity Inc (RVTY), listing its major shareholders and their respective proportions. It also outlines institutional holdings over time, showing the number of institutions and shares held quarterly, alongside the top institutional movements. Additionally, the article identifies types …